Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Product added to your cart successfully
The main challenge is potential irritation at very high concentrations (above 20%), but formulations between 10-20% are generally safe and effective
BLU-945, a selective EGFR inhibitor, was tested in EGFR-mutated NSCLC (NCT04862780), while daraxonrasib, a RAS(ON) multiselective noncovalent tri-complex inhibitor, is being evaluated in both NSCLC (NCT06881784) and PDAC (NCT06625320)
Journal of Mental Science
US$ 21.09
US$ 24.53
US$ 23.54
US$ 21.61
US$ 27.96
